ReviewPituitary2020
Common tools for pituitary adenomas research: cell lines and primary cells.
Review in Pituitary, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Article
- Generation of Functional GnRH-Responsive Pituitary-like Organoids from Ovine Embryonic Stem Cells.Cells · 2026Article
- Article
- Plumbagin Induces Ferroptosis in Nonfunctioning Pituitary Adenomas via Nrf2/FTH1-Dependent Ferritinophagy.Drug design, development and therapy · 2026Article
- miR-29a-3p compositely regulates the COL6A6/PTEN-PI3K/Akt/CUX1 feedback loop to participate in the proliferation and invasion of pituitary adenomas.Journal of molecular histology · 2025Article
- Recent Advances in Ionic Mechanisms in Pituitary Cells: Implications for Electrophysiological and Electropharmacological Research.Journal of clinical medicine · 2025Review
- Spliceosome component TCERG1 regulates the aggressiveness of somatotroph adenoma.Journal of endocrinological investigation · 2025Article
- Bromocriptine sensitivity in bromocriptine-induced drug-resistant prolactinomas is restored by inhibiting FGF19/FGFR4/PRL.Journal of endocrinological investigation · 2025Article
- EndoCompass Project: Research Roadmap for Pituitary and Neuroendocrine Tumor Endocrinology.Hormone research in paediatrics · 2025Review
- NET Models Meeting 2024 white paper: the current state of neuroendocrine tumour research models and our future aspirations.Endocrine oncology (Bristol, England) · 2024Review
- Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues.Cancer cell international · 2023Article
- Organoid models of the pituitary gland in health and disease.Frontiers in endocrinology · 2023Review
- Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism.American journal of human genetics · 2022Article
- MiR-106b-5p regulates esophageal squamous cell carcinoma progression by binding to HPGD.BMC cancer · 2022Article
- Neurosurgical Approaches to Brain Tissue Harvesting for the Establishment of Cell Cultures in Neural Experimental Cell Models.Materials (Basel, Switzerland) · 2021Review
- Pituitary Tumors and Immortalized Cell Lines Generated by Cre-Inducible Expression of SV40 T Antigen.Endocrinology · 2021Article
- Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches.Frontiers in endocrinology · 2021Review
- PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
purposePituitary tumor is the common primary brain tumor in humans. For further studying the pathogenesis and new therapeutic targets of pituitary adenoma, cell lines and primary cells are necessary tools. Different from primary cells that have short survival time and hormone secretion maintenance time, cell lines would be endowed with immortal characteristics under the help of gene modification. This review is to explore whether these cell lines still have similar pathophysiological changes in pituitary adenoma cells and methods to prolong the lifespan of pituitary adenoma primary cells.
resultsIn the cell lines summarized in the review, HP75, PDFS, HPA and GX were derived from human pituitary adenomas. It was found that the cell lines commonly used in articles published between January 2014 and July 2019 were GH3, AtT20, MMQ, GH4C1, HP75 and TtT/GF. Besides, it was glad that many methods had been used to prolong the lifespan and maintain characteristics of pituitary adenoma primary cells.
conclusionThe paper reviews most of pituitary adenoma cell lines that have been successfully established since 1968 and the relevant situation of primary culture of pituitary adenoma cells. Obviously, it requires us to make more efforts to obtain human pituitary adenoma cell lines and prolong the lifespan of pituitary adenoma primary cells with maintaining their morphology and ability to secret hormones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.